close
 To:

From:

Partner News

Our partnership strategy has enabled us to build a broad product pipeline and to create an annuity of license fees, milestone payments and royalty revenues while limiting development expenses. This strategy enables us to remain focused on research and development and to discover new drugs and expand our and our partners' pipelines. Please check here for updates on news, event participation and important scientific publications from our partners.

News

2012-04-30 Regulus Therapeutics Appoints Bruce Carter to its Board of Directors
2012-04-23 Regulus Receives Allowance from Japan and U.S. Patent Offices for HCV Intellectual Property
2012-03-08 OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2011 and Provides Update on Clinical Development Program
2012-03-08 Teva and OncoGenex Announce Updates to Custirsen Development Program in Advanced Prostate Cancer
2012-02-29 Terms Sheet Agreement to Further Develop ATL1102
2012-02-27 OncoGenex Announces Data Highlighting OGX-427 at 27th Annual European Association of Urology Congress
2012-02-16 Regulus Announces New Publication Showing Potential Therapeutic Benefit of Targeting microRNA-21 in Fibrosis
2012-02-09 ATL1103 Development Update
2012-02-02 Clinical Data on OGX-427 Presented at the ASCO 2012 Genitourinary Cancers Symposium Provide Ongoing Evidence of Hsp27 as a Potential Therapeutic Target in Advanced Prostate Cancer
2012-02-02 Phase 1 Study of OGX-427 Presented at the ASCO 2012 Genitourinary Cancers Symposium Shows Early Evidence of Activity in Bladder Cancer
2012-01-19 OncoGenex Announces Presentation of OGX-427 Data at the ASCO 2012 Genitourinary Cancers Symposium
2012-01-05 Regulus Therapeutics to Present microRNA Platform and Pipeline Updates
2012-01-04 OncoGenex Announces Publication of Phase I/II Custirsen (OGX-011/TV-1011) Data in Journal of Thoracic Oncology
2011-12-12 Regulus Therapeutics Initiates an Orphan and Rare Disease microRNA Therapeutic Effort in Brain Cancer
2011-12-07 ATL1103 Successfully Progresses Towards Phase II Clinical Trial
2011-11-22 Pfizer to Acquire Excaliard Pharmaceuticals
2011-11-08 Regulus Therapeutics to Present New In Vivo Data for microRNA-21 in Kidney Fibrosis
2011-11-07 ATL1103 Japanese Patent Granted
2011-11-02 Regulus Therapeutics Expands Worldwide Patent Coverage on microRNA-122 to Treat Hepatitis C Virus (HCV) Infection
2011-10-26 OncoGenex Announces Publication of OGX-427 Pre-Clinical Data in Pancreatic Cancer
2011-10-20 Regulus Therapeutics and Collaborators Publish New Pre-clinical Data on microRNA-33 Demonstrating Key Role in Cholesterol Homeostasis and Fatty Acid Metabolism
2011-10-20 OncoGenex Pharmaceuticals Initiates an International, Randomized, Phase II Clinical Trial Evaluating OGX-427 in Advanced Bladder Cancer
2011-10-11 Dosing Completed in ATL1103 Clinical Trial
2011-09-26 iCo Therapeutics and JDRF Partner to Investigate iCo-007 in Diabetic Macular Edema
2011-09-21 A Phase III Clinical Trial Testing Long-Term Pain Management in Men With Metastatic Castrate-Resistant Prostate Cancer Is Open and Enrolling
2011-09-20 ATL1102 New Stem Cell Mobilization Indication - Internatinoal Patent Application Lodged
2011-09-19 OncoGenex Announces Completion of a Special Protocol Assessment (SPA) Amendment with the FDA Increasing Patient Eligibility for the Custirsen Phase III Prostate Cancer SATURN Clinical Trial
2011-09-14 Dosing Commences in Final Stage of Clinical Trial of ATL1103
2011-09-08 Regulus Therapeutics to Present New Advancements in microRNA Therapeutics for Treatment of Metabolic Diseases and Cancer
2011-09-06 OncoGenex Announces Publication of Custirsen Phase II Clinical and Pre-Clinical Data in Leading Cancer Journals
2011-08-15 iCo Therapeutics Announces Key iCo-007 Clinical Development Milestone
2011-07-20 Regulus Therapeutics and GlaxoSmithKline Name a Third Alliance microRNA Target Triggering a Preclinical Milestone Payment
2011-07-14 Regulus Therapeutics Appoints Gregory Hannon, Ph.D. to Scientific Advisory Board
2011-06-29 Dosing Commences in Clinical Trial of ATL1103
2011-06-15 Approval to Commence Phase I Clinical Trial of ATL1103
2011-06-09 ANP Receives Funding to Complete Additional Key Studies on ATL1103
2011-06-08 Regulus Announces the Publication of a Nature Article Implicating microRNAs in the Pathogenesis of Obesity and Type 2 Diabetes
2011-06-06 Data from Pre-Clinical Studies Presented at the 2011 ASCO Annual Meeting Show Potential Combinability of Custirsen with MDV3100 and Hsp90 Inhibitors to Enhance Anti-Tumor Activity in Prostate Cancer
2011-06-06 Regulus Therapeutics and Collaborators from NYU Langone Medical Center Publish New Data Demonstrating Clearance of Cholesterol from Bloodstream and Reduction of Atherosclerotic Plaques through Inhibition of microRNA-33
2011-05-19 Teva and OncoGenex to Present Data on Custirsen in Prostate Cancer at the 2011 ASCO Annual Meeting
2011-05-18 Regulus Therapeutics Expands Executive Team with Recent Appointments
2011-05-13 iCo Therapeutics Inc. Engages Ora for Ophthalmic Clinical & Regulatory Guidance

About Isis

We know that sick people depend on us, and we have the technology to change the way diseases are treated.

Learn More

Strategic Alliances

Our business strategy is to do what we do best — to discover antisense drugs. We look for the right partners to help us produce and commercialize our drugs, and we've had tremendous success with both small and global pharmaceutical partners.

Learn More